ASCO GU 2020: A Novel GnRH Antagonist Formulation Leads to Undetectable Testosterone for ≥6 Months in an Animal Model
The agent is under investigation in men with advanced prostate cancer.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.